Purpose: To investigate the effectiveness and safety of bevacizumab-paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice.
Methods: In this prospective multicenter observational study, bevacizumab-paclitaxel was administered at the discretion of attending physicians. Cohorts A and B had hormone receptor-positive and triple-negative breast cancer (TNBC), respectively. Primary endpoint was overall survival (OS). Multivariate analyses were conducted to identify prognostic factors.
Results: Between November 2012 and October 2014, 767 patients were enrolled from 155 institutions across Japan. Effectiveness was analyzed in 754 eligible patients (cohort A, 539; cohort B, 215) and safety in 750 treated patients (median observation period, 19.7 months). Median OS (95% CI) was 21.7 (19.8-23.6) months in eligible patients; 25.2 (22.4-27.4) months and 13.2 (11.3-16.6) months in cohorts A and B, respectively; and 24.4 (21.9-27.2) months and 17.6 (15.2-20.0) months in patients receiving first- and second-line therapy, respectively. Factors affecting OS (hazard ratio 95% CI) were TNBC (1.75, 1.44-2.14), second-line therapy (1.35, 1.13-1.63), ECOG performance status ≥ 1 (1.28, 1.04-1.57), taxane-based chemotherapy (0.65, 0.49-0.86), cancer-related symptoms (0.56, 0.46-0.68), and visceral metastasis (0.52, 0.40-0.66). Incidences of grade ≥ 3 AEs hypertension, neutropenia, peripheral neuropathy, proteinuria, and bleeding were 35.7%, 27.2%, 7.2%, 3.7%, and 0.3%, respectively.
Conclusions: In Japanese clinical practice, combined bevacizumab-paclitaxel was as effective as in previous studies. Factors that independently predicted poor prognosis in the present study are consistent with those identified previously.
Trial Registration: Trial no. UMIN000009086.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796874 | PMC |
| http://dx.doi.org/10.1007/s12282-020-01138-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resolving spatially distinct phytohormone response zones in Arabidopsis thaliana roots colonized by Fusarium oxysporum.
J Exp Bot
January 2025
Plant-Fusarium Interactions Research Team, School of BioSciences, University of Melbourne, Parkville, Australia.
Jasmonic acid (JA), ethylene (ET) and salicylic acid (SA) are the three major phytohormones coordinating plant defense responses, and all three are implicated in the defense against the fungal pathogen Fusarium oxysporum. However, their distinct modes of action and possible interactions remain unknown, in part because all spatial information on their activity is lacking. Here, we set out to probe this spatial aspect of plant immunity by using live-microscopy with newly developed fluorescence-based transcriptional reporter lines.
View Article and Find Full Text PDFSex-based analysis of status epilepticus management and outcome: A cohort study.
Epilepsia
January 2025
Department of Clinical Neurosciences, Neurology Service, CHUV and University of Lausanne, Lausanne, Switzerland.
Status epilepticus (SE) is a neurological emergency with significant morbidity and mortality. The role of sex as a factor influencing the characteristics, treatment, and outcomes of SE has been scarcely addressed. This study investigates this variable regarding the clinical management and outcome among adult patients with SE.
View Article and Find Full Text PDFTyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.
Clin Lymphoma Myeloma Leuk
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:
Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.
Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.
Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.
Impact of air pollution on the clinical exacerbation of central demyelinating disease: A 10-year data from the Northern Thailand MS and NMOSD registry.
Mult Scler Relat Disord
January 2025
Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; The Northern Neuroscience Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address:
Background: Particulate matter (PM) 2.5 (PM2.5) and PM10 are implicated in neurological diseases, yet their impact on central demyelinating diseases like multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) remains unclear.
View Article and Find Full Text PDFPrognostic impact of primary versus secondary resistance to sorafenib in patients with HCC.
Ther Adv Med Oncol
January 2025
School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Background: Sorafenib is a first-line treatment option for patients with hepatocellular carcinoma (HCC). However, the impact of sorafenib resistance type on patient survival prediction and choice of second-line treatment regimen is unknown.
Objectives: This study aims to explore the factors predicting resistance in patients with HCC receiving sorafenib, the impact of resistance on survival, and the optimal second-line treatment regimen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!